IFNB1 and myositis disease: Dazukibart, an IFNβ-specific monoclonal antibody, resulted in a marked reduction in disease activity of myositis patients in a phase 2 trial [16], supporting IFNβ inhibition as a highly promising therapeutic strategy in adults with DM.